Skip to main content

Table 10 Advances of FGFR-TKIs

From: Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

Drug

Brand name

Manufacturer

Targets

Applications of diseases

Approved years or current phase of clinical trials

Erdafitinib

Balversa

Janssen

FGFR1-4

FGFR2/3-alterated locally advanced or metastatic urothlial cancer that has progressed during or following platinum-containing chemotherapy 

2019 [166]

Pemigatinib

Pemazyre

Incyte

FGFR1-3

 Previously treated, unresectable locally advanced or metastatic CCA with FGFR2 fusion+ or other rearrangement

2020 [167]

Investigational drugs

 Futibatinib

-

Taiho Oncology

FGFR1-4

FGFR2-rearranged advanced intrahepatic CCA

III (NCT04093362)

FGFR1-4 rearranged solid tumors

II (NCT04189445)

FGFR-amplifiled MBC

II (NCT04024436)

 Infigratinib

-

Novartis Oncology

FGFR1-3

 previously treated advanced FGFR3-rearranged urothlial cancer

 previously treated advanced FGFR2-rearranged CCA

II [164]

II [168]

  1. In the last column of “Approval years or current phases of clinical trials”: erdafitinib and pemigatinib were firstly by Food and Drug Administration (FDA); other two drugs are under investigation, we provided current phases of their clinical trials
  2. CCA cholangiocarcinoma, MBC metastatic breast cancer, FGFR fibroblast growth factor receptor
  3. Data source: www.fda.govwww.drugs.com, and www.clinicaltrials.gov (cutoff date: 19 July 2020)